抗真菌药物市场－全球产业规模、份额、趋势、机会和预测，按药物类别、适应症、感染类型、给药途径、最终用户、配销通路、地区和竞争情况划分，2020 年至 2030 年

2024 年全球抗真菌药物市场价值为 124.7 亿美元，预计在预测期内将呈现显着增长，到 2030 年的复合年增长率将达到 4.33%。抗真菌药物通常用于治疗真菌感染。这些药物可以口服、外用或静脉注射给药。酵母菌感染、癣、指甲和皮肤病等真菌感染可能是由土壤、空气和皮肤中的真菌引起的。吸入真菌孢子也可能导致呼吸问题。因此，免疫系统较弱的人更容易受到真菌感染，需要使用抗真菌药物。大多数此类药物需要医生处方，但也有少数可以在柜檯购买。

抗霉菌药物主要分为两类：局部用药和全身用药。根据所治疗的特定病症，局部用药通常外用或阴道给药，而全身用药则口服或静脉注射。全身性用药的例子包括伊曲康唑、氟康唑、酮康唑、伏立康唑、泊沙康唑和艾沙康唑。抗真菌药物可以透过两种方式发挥作用：直接杀死真菌细胞或抑制其生长发育。此外，抗真菌药物透过靶向真菌细胞中必需但人类细胞中非必需的结构或功能来发挥作用，使其能够在不损害人体细胞的情况下对抗真菌感染。真菌细胞膜和细胞壁通常是靶向成分，因为它们包围并保护真菌细胞。任何一种结构的破坏都可能导致真菌细胞破裂和死亡。

关键市场驱动因素

真菌感染盛行率上升

主要市场挑战

不良健康影响

主要市场趋势

研发活动数量的增加

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球抗霉菌药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类别（唑类、棘白菌素类、多烯类、烯丙胺类、其他）
  • 依适应症（念珠菌症、曲菌病、毛霉菌病、皮癣菌症等）
  • 依感染类型（表浅真菌感染、全身性真菌感染）
  • 依给药途径（局部、口服、肠胃外、其他）
  • 按最终使用者（家庭护理、医院、诊所、其他）
  • 按配销通路（零售药局、医院药局、网路药局）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美抗霉菌药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗真菌药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太抗真菌药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲抗霉菌药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲抗真菌药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球抗真菌药物市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Abbott Laboratories Inc.
• Astellas Pharma Inc.
• Bayer AG
• GSK plc
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Mycovia Pharmaceuticals, Inc.
• Apex Laboratories Pvt. Ltd.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Anti-Fungal Drugs Market was valued at USD 12.47 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.33% through 2030. Antifungal medications are commonly prescribed to treat fungal infections. These medications can be administered orally, topically, or intravenously via an IV drip. Fungal infections such as yeast infections, ringworm, nail and skin diseases can be caused by fungi present in the soil, air, and skin. Inhaling fungal spores may also lead to respiratory issues. Therefore, individuals with weakened immune systems are more susceptible to fungal infections, necessitating the use of antifungal medication. Most of these medications require a doctor's prescription, although a few are available over the counter.

There are two main categories of antifungal drugs: local and systemic. Depending on the specific condition being treated, local antifungals are commonly applied topically or vaginally, while systemic antifungals are administered orally or intravenously. Examples of systemically administered medicines include itraconazole, fluconazole, ketoconazole, voriconazole, posaconazole, and isavuconazole. Antifungal medications can function in one of two ways: they can directly kill fungal cells or inhibit their growth and development. Moreover, antifungal medications work by targeting structures or functions that are essential in fungal cells but not in human cells, allowing them to combat fungal infections without harming human cells. The fungal cell membrane and cell wall are frequently targeted components, as they surround and protect the fungal cell. Compromising either of these structures can cause the fungal cell to burst open and die.

Key Market Drivers

Rising Prevalence of Fungal Infections

The increasing prevalence of fungal infections is a key driver for the revenue growth in the market. Research indicates that fungal pathogens are responsible for approximately 13 million infections and 1.5 million deaths worldwide each year. Antifungal medications are also administered orally. On March 30, 2023, GSK plc and SCYNEXIS, Inc. announced an exclusive license agreement for Brexafemme, a first-in-class antifungal approved by the U.S. Food and Drug Administration (FDA) for the treatment of Vulvovaginal Candidiasis (VVC) and the reduction of the incidence of recurrent VVC (RVVC). This exclusive licensing deal grants GSK the sole right to commercialize Brexafemme for VVC and RVVC while continuing the development of ibrexafungerp, which is currently in phase III clinical trials for the possible treatment of Invasive Candidiasis (IC), a potentially fatal fungal infection.

The prevalence of fungal infections has been on the rise in recent years, prompting concerns within the healthcare industry. Contributing factors to this alarming trend include increasing global temperatures, the prevalence of chronic illnesses, and compromised immune systems. Hospital-acquired fungal infections, or nosocomial infections, have become a significant concern, with approximately 1.7 million hospitalized patients contracting such infections in 2019, according to the Centers for Disease Control and Prevention (CDC).

Key Market Challenges

Adverse Health Effects

There are several disadvantages associated with antifungal drugs. One key factor is that individuals with weakened immune systems, such as those with acquired immunodeficiency syndrome (AIDS), lupus, cancer, and other conditions, are more susceptible to dangerous fungal infections known as opportunistic infections. This vulnerability poses a challenge to the revenue growth of the antifungal drug market.

Furthermore, the type of medicine, dosage strength, and the specific fungus being treated can all influence the outcome of the medication. Common side effects may include pain in the abdomen, unsettled stomach, diarrhea, and itchy, scorching, or rashy skin. These symptoms can also have a negative impact on the revenue growth of the market.

In addition to these challenges, antifungal medication can produce major side effects, including liver damage such as jaundice, anaphylaxis, and other severe allergic responses. Blisters and peeling skin are also symptoms of severe allergic skin reactions that can occur as a result of using antifungal drugs. Considering these factors, it becomes evident that while antifungal drugs are necessary for treating fungal infections, they do come with significant drawbacks that need to be taken into account.

Key Market Trends

Increase In the Number of Research and Development Activities

The increase in the number of research and development (R&D) activities in the field of antifungal drugs is expected to significantly boost the demand for these medications. Antifungal drugs are critical for treating a wide range of fungal infections, from superficial conditions like athlete's foot to life-threatening systemic infections. Increasing R&D investments lead to the discovery of new antifungal compounds and formulations. These innovations are likely to result in the development of more effective drugs with improved mechanisms of action, enhancing the arsenal of treatment options available. R&D efforts are dedicated to understanding and combating antifungal resistance. Researchers are working to identify the mechanisms behind resistance and develop strategies to overcome it. This will ensure the continued effectiveness of antifungal drugs, driving their demand. Research in the field of fungal biology is uncovering specific molecular targets within fungal cells that can be exploited for drug development. Targeted therapies can enhance drug efficacy and reduce side effects, making antifungal drugs more appealing to healthcare providers and patients.

Key Market Players

• Abbott Laboratories Inc.
• Astellas Pharma Inc.
• Bayer AG
• GSK plc
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Mycovia Pharmaceuticals, Inc.
• Apex Laboratories Pvt. Ltd.

Report Scope:

In this report, the Global Anti-Fungal Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Fungal Drugs Market, By Drug Class:

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others

Anti-Fungal Drugs Market, By Indication:

• Candidiasis
• Aspergillosis
• Mucormycosis
• Dermatophytosis
• Others

Anti-Fungal Drugs Market, By Infection Type:

• Superficial Fungal Infection
• Systemic Fungal Infection

Anti-Fungal Drugs Market, By Route of Administration:

• Topical
• Oral
• Parenteral
• Others

Anti-Fungal Drugs Market, By End User:

• Homecare
• Hospitals
• Clinics
• Others

Anti-Fungal Drugs Market, By Distribution Channel:

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Anti-Fungal Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Fungal Drugs Market.

Available Customizations:

Global Anti-Fungal Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Fungal Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
  • 5.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
  • 5.2.3. By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection)
  • 5.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
  • 5.2.5. By End User (Homecare, Hospitals, Clinics, Others)
  • 5.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
  • 5.2.7. By Region
  • 5.2.8. By Company (2024)
• 5.3. Market Map

6. North America Anti-Fungal Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Indication
  • 6.2.3. By Infection Type
  • 6.2.4. By Route Of Administration
  • 6.2.5. By End User
  • 6.2.6. By Distribution Channel
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Fungal Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Infection Type
      • 6.3.1.2.4. By Route Of Administration
      • 6.3.1.2.5. By End User
      • 6.3.1.2.6. By Distribution Channel
  • 6.3.2. Canada Anti-Fungal Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Infection Type
      • 6.3.2.2.4. By Route Of Administration
      • 6.3.2.2.5. By End User
      • 6.3.2.2.6. By Distribution Channel
  • 6.3.3. Mexico Anti-Fungal Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Infection Type
      • 6.3.3.2.4. By Route Of Administration
      • 6.3.3.2.5. By End User
      • 6.3.3.2.6. By Distribution Channel

7. Europe Anti-Fungal Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Indication
  • 7.2.3. By Infection Type
  • 7.2.4. By Route Of Administration
  • 7.2.5. By End User
  • 7.2.6. By Distribution Channel
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Fungal Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Infection Type
      • 7.3.1.2.4. By Route Of Administration
      • 7.3.1.2.5. By End User
      • 7.3.1.2.6. By Distribution Channel
  • 7.3.2. United Kingdom Anti-Fungal Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Infection Type
      • 7.3.2.2.4. By Route Of Administration
      • 7.3.2.2.5. By End User
      • 7.3.2.2.6. By Distribution Channel
  • 7.3.3. Italy Anti-Fungal Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Infection Type
      • 7.3.3.2.4. By Route Of Administration
      • 7.3.3.2.5. By End User
      • 7.3.3.2.6. By Distribution Channel
  • 7.3.4. France Anti-Fungal Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Infection Type
      • 7.3.4.2.4. By Route Of Administration
      • 7.3.4.2.5. By End User
      • 7.3.4.2.6. By Distribution Channel
  • 7.3.5. Spain Anti-Fungal Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Infection Type
      • 7.3.5.2.4. By Route Of Administration
      • 7.3.5.2.5. By End User
      • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Anti-Fungal Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Indication
  • 8.2.3. By Infection Type
  • 8.2.4. By Route Of Administration
  • 8.2.5. By End User
  • 8.2.6. By Distribution Channel
  • 8.2.7. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Anti-Fungal Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Infection Type
      • 8.3.1.2.4. By Route Of Administration
      • 8.3.1.2.5. By End User
      • 8.3.1.2.6. By Distribution Channel
  • 8.3.2. India Anti-Fungal Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Infection Type
      • 8.3.2.2.4. By Route Of Administration
      • 8.3.2.2.5. By End User
      • 8.3.2.2.6. By Distribution Channel
  • 8.3.3. Japan Anti-Fungal Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Infection Type
      • 8.3.3.2.4. By Route Of Administration
      • 8.3.3.2.5. By End User
      • 8.3.3.2.6. By Distribution Channel
  • 8.3.4. South Korea Anti-Fungal Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Infection Type
      • 8.3.4.2.4. By Route Of Administration
      • 8.3.4.2.5. By End User
      • 8.3.4.2.6. By Distribution Channel
  • 8.3.5. Australia Anti-Fungal Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Infection Type
      • 8.3.5.2.4. By Route Of Administration
      • 8.3.5.2.5. By End User
      • 8.3.5.2.6. By Distribution Channel

9. South America Anti-Fungal Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Indication
  • 9.2.3. By Infection Type
  • 9.2.4. By Route Of Administration
  • 9.2.5. By End User
  • 9.2.6. By Distribution Channel
  • 9.2.7. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Anti-Fungal Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Infection Type
      • 9.3.1.2.4. By Route Of Administration
      • 9.3.1.2.5. By End User
      • 9.3.1.2.6. By Distribution Channel
  • 9.3.2. Argentina Anti-Fungal Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Infection Type
      • 9.3.2.2.4. By Route Of Administration
      • 9.3.2.2.5. By End User
      • 9.3.2.2.6. By Distribution Channel
  • 9.3.3. Colombia Anti-Fungal Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Infection Type
      • 9.3.3.2.4. By Route Of Administration
      • 9.3.3.2.5. By End User
      • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Anti-Fungal Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Indication
  • 10.2.3. By Infection Type
  • 10.2.4. By Route Of Administration
  • 10.2.5. By End User
  • 10.2.6. By Distribution Channel
  • 10.2.7. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Anti-Fungal Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Infection Type
      • 10.3.1.2.4. By Route Of Administration
      • 10.3.1.2.5. By End User
      • 10.3.1.2.6. By Distribution Channel
  • 10.3.2. Saudi Arabia Anti-Fungal Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Infection Type
      • 10.3.2.2.4. By Route Of Administration
      • 10.3.2.2.5. By End User
      • 10.3.2.2.6. By Distribution Channel
  • 10.3.3. UAE Anti-Fungal Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Infection Type
      • 10.3.3.2.4. By Route Of Administration
      • 10.3.3.2.5. By End User
      • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Anti-Fungal Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Astellas Pharma Inc.
• 15.3. Bayer AG
• 15.4. GSK plc
• 15.5. Glenmark Pharmaceuticals Limited
• 15.6. Merck & Co. Inc.
• 15.7. Novartis AG
• 15.8. Pfizer Inc.
• 15.9. Mycovia Pharmaceuticals, Inc.
• 15.10. Apex Laboratories Pvt. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer